

William E Whitehead

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/759742/publications.pdf>

Version: 2024-02-01

141
papers

21,036
citations

15466

65
h-index

11288

136
g-index

142
all docs

142
docs citations

142
times ranked

9127
citing authors

#	ARTICLE	IF	CITATIONS
1	Proinflammatory Diet Is Associated With Increased Risk of Fecal Incontinence Among Older Women: Prospective Results From the Nurses' Health Study. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 1657-1659.e3.	2.4	2
2	Greater Overlap of Rome IV Disorders of Gut-Brain Interactions Leads to Increased Disease Severity and Poorer Quality of Life. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e945-e956.	2.4	52
3	Functional Gastrointestinal Disorders and Associated Health Impairment in Individuals with Celiac Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1315-1325.e4.	2.4	9
4	Disorders of gut-brain interaction: Highly prevalent and burdensome yet under-recognized within medical education. <i>United European Gastroenterology Journal</i> , 2022, 10, 736-744.	1.6	10
5	Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study. <i>Gastroenterology</i> , 2021, 160, 99-114.e3.	0.6	913
6	Rome IV Functional Gastrointestinal Disorders and Health Impairment in Subjects With Hypermobility Spectrum Disorders or Hypermobile Ehlers-Danlos Syndrome. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 277-287.e3.	2.4	29
7	A multicenter study of anorectal pressures and rectal sensation measured with portable manometry in healthy women and men. <i>Neurogastroenterology and Motility</i> , 2021, 33, e14067.	1.6	14
8	Chronic constipation in adults: Contemporary perspectives and clinical challenges. 2: Conservative, behavioural, medical and surgical treatment. <i>Neurogastroenterology and Motility</i> , 2021, 33, e14070.	1.6	17
9	Validity and Reliability of the Malay Versions of Bloating Severity (BSQ-M) and Quality of Life (BLQoL-M) Questionnaires. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 2487.	1.2	2
10	Comparative effectiveness of biofeedback and injectable bulking agents for treatment of fecal incontinence: Design and methods. <i>Contemporary Clinical Trials</i> , 2021, 107, 106464.	0.8	4
11	Phenotypic profile clustering pragmatically identifies diagnostically and mechanistically informative subgroups of chronic pain patients. <i>Pain</i> , 2021, 162, 1528-1538.	2.0	19
12	Health care utilization of individuals with Rome IV irritable bowel syndrome in the general population. <i>United European Gastroenterology Journal</i> , 2021, 9, 1178-1188.	1.6	18
13	ACG Clinical Guidelines: Management of Benign Anorectal Disorders. <i>American Journal of Gastroenterology</i> , 2021, 116, 1987-2008.	0.2	58
14	Fecal Incontinence Diagnosed by the Rome IV Criteria in the United States, Canada, and the United Kingdom. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 385-391.	2.4	37
15	The international anorectal physiology working group (IAPWG) recommendations: Standardized testing protocol and the London classification for disorders of anorectal function. <i>Neurogastroenterology and Motility</i> , 2020, 32, e13679.	1.6	184
16	Prevalence of Rome IV Functional Bowel Disorders Among Adults in the United States, Canada, and the United Kingdom. <i>Gastroenterology</i> , 2020, 158, 1262-1273.e3.	0.6	249
17	A genetic polymorphism that is associated with mitochondrial energy metabolism increases risk of fibromyalgia. <i>Pain</i> , 2020, 161, 2860-2871.	2.0	17
18	Functional gastrointestinal disorders are increased in joint hypermobility-related disorders with concomitant postural orthostatic tachycardia syndrome. <i>Neurogastroenterology and Motility</i> , 2020, 32, e13975.	1.6	19

#	ARTICLE	IF	CITATIONS
19	Fecal Incontinence. , 2020, , 427-430.		0
20	Controlling faecal incontinence in women by performing anal exercises with biofeedback or loperamide: a randomised clinical trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 698-710.	3.7	44
21	Anorectal physiology in health: A randomized trial to determine the optimum catheter for the balloon expulsion test. <i>Neurogastroenterology and Motility</i> , 2019, 31, e13582.	1.6	1
22	Subgroups of IBS patients are characterized by specific, reproducible profiles of GI and non-GI symptoms and report differences in healthcare utilization: A population-based study. <i>Neurogastroenterology and Motility</i> , 2019, 31, e13483.	1.6	28
23	The Prevalence and Risk of Fecal Incontinence in Patients with Cystic Fibrosis: Nothing to Sneeze At. <i>Digestive Diseases and Sciences</i> , 2018, 63, 818-819.	1.1	0
24	Epidemiology, clinical characteristics, and associations for symptom-based Rome IV functional dyspepsia in adults in the USA, Canada, and the UK: a cross-sectional population-based study. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 252-262.	3.7	199
25	Relationship between symptoms and quality of life in fecal incontinence. <i>Neurogastroenterology and Motility</i> , 2018, 30, e13241.	1.6	22
26	The Prevalence and Impact of Overlapping Rome IV-Diagnosed Functional Gastrointestinal Disorders on Somatization, Quality of Life, and Healthcare Utilization: A Cross-Sectional General Population Study in Three Countries. <i>American Journal of Gastroenterology</i> , 2018, 113, 86-96.	0.2	138
27	Physical Activity, BMI, and Risk of Fecal Incontinence in the Nurses' Health Study. <i>Clinical and Translational Gastroenterology</i> , 2018, 9, e200.	1.3	20
28	If We Don't Ask, They Won't Tell: Screening for Urinary and Fecal Incontinence by Primary Care Providers. <i>Journal of the American Board of Family Medicine</i> , 2018, 31, 774-782.	0.8	28
29	Systemic cytokines are elevated in a subset of patients with irritable bowel syndrome but largely unrelated to symptom characteristics. <i>Neurogastroenterology and Motility</i> , 2018, 30, e13378.	1.6	16
30	Increased Long-term Dietary Fiber Intake Is Associated With a Decreased Risk of Fecal Incontinence in Older Women. <i>Gastroenterology</i> , 2018, 155, 661-667.e1.	0.6	30
31	How the Change in IBS Criteria From Rome III to Rome IV Impacts on Clinical Characteristics and Key Pathophysiological Factors. <i>American Journal of Gastroenterology</i> , 2018, 113, 1017-1025.	0.2	90
32	The global prevalence of IBS in adults remains elusive due to the heterogeneity of studies: a Rome Foundation working team literature review. <i>Gut</i> , 2017, 66, 1075-1082.	6.1	368
33	Rome foundation Asian working team report: Real world treatment experience of Asian patients with functional bowel disorders. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 1450-1456.	1.4	29
34	Management of the multiple symptoms of irritable bowel syndrome. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 112-122.	3.7	54
35	Menopausal Hormone Therapy Is Associated With Increased Risk of Fecal Incontinence in Women After Menopause. <i>Gastroenterology</i> , 2017, 152, 1915-1921.e1.	0.6	24
36	Editorial: <sc>ONO</sc>â€2952 in irritable bowel syndrome with diarrhoea â€“ authorsâ€™ reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 1005-1005.	1.9	0

#	ARTICLE	IF	CITATIONS
37	Irritable bowel syndrome: what do the new Rome IV diagnostic guidelines mean for patient management?. Expert Review of Gastroenterology and Hepatology, 2017, 11, 281-283.	1.4	46
38	Brief telephone-delivered cognitive behavioral therapy targeted to parents of children with functional abdominal pain: a randomized controlled trial. Pain, 2017, 158, 618-628.	2.0	49
39	Update on Rome IV Criteria for Colorectal Disorders: Implications for Clinical Practice. Current Gastroenterology Reports, 2017, 19, 15.	1.1	181
40	Patient preferences for endpoints in fecal incontinence treatment studies. Neurogastroenterology and Motility, 2017, 29, e13032.	1.6	11
41	Randomised clinical trial: exploratory phase 2 study of ONO-2952 in diarrhoea-predominant irritable bowel syndrome. Alimentary Pharmacology and Therapeutics, 2017, 45, 14-26.	1.9	16
42	Improving biofeedback for the treatment of fecal incontinence in women: implementation of a standardized multi-site manometric biofeedback protocol. Neurogastroenterology and Motility, 2017, 29, e12906.	1.6	19
43	Fecal incontinence in irritable bowel syndrome: Prevalence and associated factors in Swedish and American patients. Neurogastroenterology and Motility, 2017, 29, e12919.	1.6	23
44	Biomarkers to distinguish functional constipation from irritable bowel syndrome with constipation. Neurogastroenterology and Motility, 2016, 28, 783-792.	1.6	17
45	Treating Fecal Incontinence: An Unmet Need in Primary Care Medicine. North Carolina Medical Journal, 2016, 77, 211-215.	0.1	19
46	Design of Treatment Trials for Functional Gastrointestinal Disorders. Gastroenterology, 2016, 150, 1469-1480.e1.	0.6	195
47	Development and Validation of the Rome IV Diagnostic Questionnaire for Adults. Gastroenterology, 2016, 150, 1481-1491.	0.6	400
48	Loperamide Versus Psyllium Fiber for Treatment of Fecal Incontinence. Diseases of the Colon and Rectum, 2015, 58, 983-993.	0.7	67
49	Validity and Reliability of the Japanese Version of the Rome III Diagnostic Questionnaire for Irritable Bowel Syndrome and Functional Dyspepsia. Journal of Neurogastroenterology and Motility, 2015, 21, 537-544.	0.8	39
50	Factors associated with fecal incontinence in a nationally representative sample of diabetic women. International Urogynecology Journal, 2015, 26, 1483-1488.	0.7	16
51	Epidemiology, Pathophysiology, and Classification of Fecal Incontinence: State of the Science Summary for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Workshop. American Journal of Gastroenterology, 2015, 110, 127-136.	0.2	219
52	Factors That Affect Consultation and Screening for Fecal Incontinence. Clinical Gastroenterology and Hepatology, 2015, 13, 709-716.	2.4	25
53	Controlling anal incontinence in women by performing anal exercises with biofeedback or loperamide (CAPABLE) trial: Design and methods. Contemporary Clinical Trials, 2015, 44, 164-174.	0.8	17
54	Treatment of Fecal Incontinence: State of the Science Summary for the National Institute of Diabetes and Digestive and Kidney Diseases Workshop. American Journal of Gastroenterology, 2015, 110, 138-146.	0.2	74

#	ARTICLE	IF	CITATIONS
55	Is ginger effective for the treatment of irritable bowel syndrome? A double blind randomized controlled pilot trial. <i>Complementary Therapies in Medicine</i> , 2014, 22, 17-20.	1.3	32
56	Episodic Nature of Symptoms in Irritable Bowel Syndrome. <i>American Journal of Gastroenterology</i> , 2014, 109, 1450-1460.	0.2	34
57	ACG Clinical Guideline: Management of Benign Anorectal Disorders. <i>American Journal of Gastroenterology</i> , 2014, 109, 1141-1157.	0.2	265
58	Validation of the Balloon Evacuation Test: Reproducibility and Agreement With Findings From Anorectal Manometry and Electromyography. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 2049-2054.	2.4	131
59	Impact of Eating Restriction on Gastrointestinal Motility in Adolescents With IBS. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2014, 58, 491-494.	0.9	7
60	Psychological Treatments in Functional Gastrointestinal Disorders: A Primer for the Gastroenterologist. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 208-216.	2.4	118
61	Association of Low Dietary Intake of Fiber and Liquids With Constipation: Evidence From the National Health and Nutrition Examination Survey. <i>American Journal of Gastroenterology</i> , 2013, 108, 796-803.	0.2	148
62	Obstetric Sphincter Injury Interacts With Diarrhea and Urgency to Increase the Risk of Fecal Incontinence in Women With Irritable Bowel Syndrome. <i>Female Pelvic Medicine and Reconstructive Surgery</i> , 2013, 19, 40-45.	0.6	9
63	Risk Factors for Fecal Incontinence in Older Women. <i>American Journal of Gastroenterology</i> , 2013, 108, 113-119.	0.2	87
64	Risk Factors for Urinary, Fecal, or Dual Incontinence in the Nurses' Health Study. <i>Obstetrics and Gynecology</i> , 2013, 122, 539-545.	1.2	90
65	IBS Patients Show Frequent Fluctuations Between Loose/Watery and Hard/Lumpy Stools: Implications for Treatment. <i>American Journal of Gastroenterology</i> , 2012, 107, 286-295.	0.2	72
66	Development and validation of new disease-specific measures of somatization and comorbidity in IBS. <i>Journal of Psychosomatic Research</i> , 2012, 73, 351-355.	1.2	16
67	Likelihood of Nursing Home Referral for Fecally Incontinent Elderly Patients is Influenced by Physician Views on Nursing Home Care and Outpatient Management of Fecal Incontinence. <i>Journal of the American Medical Directors Association</i> , 2012, 13, 350-354.	1.2	8
68	Validity and reliability of the Malay language translation of the Rome III Diagnostic Questionnaire for irritable bowel syndrome. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 746-750.	1.4	20
69	Rome III survey of irritable bowel syndrome among ethnic Malays. <i>World Journal of Gastroenterology</i> , 2012, 18, 6475.	1.4	33
70	Lubiprostone does not influence visceral pain thresholds in patients with irritable bowel syndrome. <i>Neurogastroenterology and Motility</i> , 2011, 23, 944.	1.6	40
71	Adopting new enrollment criteria for pharmaceutical trials in constipation: look before leaping. <i>Therapeutic Advances in Gastroenterology</i> , 2011, 4, 165-168.	1.4	2
72	Mindfulness Training Reduces the Severity of Irritable Bowel Syndrome in Women: Results of a Randomized Controlled Trial. <i>American Journal of Gastroenterology</i> , 2011, 106, 1678-1688.	0.2	218

#	ARTICLE	IF	CITATIONS
73	Is Fecal Incontinence a Risk Factor for Institutionalization in the Elderly?. American Journal of Gastroenterology, 2011, 106, 366-367.	0.2	6
74	Fecal incontinence in primary care: prevalence, diagnosis, and health care utilization. American Journal of Obstetrics and Gynecology, 2010, 202, 493.e1-493.e6.	0.7	97
75	Survey of Geriatricians on the Effect of Fecal Incontinence on Nursing Home Referral. Journal of the American Geriatrics Society, 2010, 58, 1058-1062.	1.3	42
76	Diagnosis and Treatment of Pelvic Floor Disorders: What's New and What to Do. Gastroenterology, 2010, 138, 1231-1235.e4.	0.6	53
77	Validation of Symptom-Based Diagnostic Criteria for Irritable Bowel Syndrome: A Critical Review. American Journal of Gastroenterology, 2010, 105, 814-820.	0.2	89
78	Inability of the Rome III Criteria to Distinguish Functional Constipation From Constipation-Subtype Irritable Bowel Syndrome. American Journal of Gastroenterology, 2010, 105, 2228-2234.	0.2	166
79	Mindfulness for irritable bowel syndrome: protocol development for a controlled clinical trial. BMC Complementary and Alternative Medicine, 2009, 9, 24.	3.7	39
80	Conservative and behavioural management of constipation. Neurogastroenterology and Motility, 2009, 21, 55-61.	1.6	25
81	Fecal Incontinence in US Adults: Epidemiology and Risk Factors. Gastroenterology, 2009, 137, 512-517.e2.	0.6	521
82	Psychometric Evaluation of Patient-Reported Outcomes in Irritable Bowel Syndrome Randomized Controlled Trials: A Rome Foundation Report. Gastroenterology, 2009, 137, 1944-1953.e3.	0.6	66
83	Irritable Bowel Syndrome Subtypes Defined by Rome II and Rome III Criteria are Similar. Journal of Clinical Gastroenterology, 2009, 43, 214-220.	1.1	57
84	Randomized Controlled Trial Shows Biofeedback to be Superior to Pelvic Floor Exercises for Fecal Incontinence. Diseases of the Colon and Rectum, 2009, 52, 1730-1737.	0.7	206
85	Complementary and alternative medicine use and cost in functional bowel disorders: A six month prospective study in a large HMO. BMC Complementary and Alternative Medicine, 2008, 8, 46.	3.7	111
86	The role of biofeedback in the treatment of gastrointestinal disorders. Nature Reviews Gastroenterology & Hepatology, 2008, 5, 371-382.	1.7	48
87	Prevalence of Symptomatic Pelvic Floor Disorders in US Women. JAMA - Journal of the American Medical Association, 2008, 300, 1311.	3.8	1,397
88	Contributions of Pain Sensitivity and Colonic Motility to IBS Symptom Severity and Predominant Bowel Habits. American Journal of Gastroenterology, 2008, 103, 2550-2561.	0.2	134
89	Is biofeedback therapy an effective treatment for dyssynergic defecation?. Nature Reviews Gastroenterology & Hepatology, 2008, 5, 74-75.	1.7	0
90	Hypnosis and upper digestive function and disease. World Journal of Gastroenterology, 2008, 14, 6276.	1.4	5

#	ARTICLE	IF	CITATIONS
91	Increased colonic pain sensitivity in irritable bowel syndrome is the result of an increased tendency to report pain rather than increased neurosensory sensitivity. <i>Gut</i> , 2007, 56, 1202-1209.	6.1	154
92	Constipation. <i>Obstetrics and Gynecology</i> , 2007, 109, 985-989.	1.2	0
93	Comorbidity in Irritable Bowel Syndrome. <i>American Journal of Gastroenterology</i> , 2007, 102, 2767-2776.	0.2	176
94	Translation and validation of a Japanese version of the irritable bowel syndrome-quality of life measure (IBS-QOL-J). <i>BioPsychoSocial Medicine</i> , 2007, 1, 6.	0.9	57
95	Costs of health care for irritable bowel syndrome, chronic constipation, functional diarrhoea and functional abdominal pain. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 26, 237-248.	1.9	177
96	The impact of fecal and urinary incontinence on quality of life 6 months after childbirth. <i>American Journal of Obstetrics and Gynecology</i> , 2007, 197, 636.e1-636.e6.	0.7	73
97	Randomized, Controlled Trial Shows Biofeedback to be Superior to Alternative Treatments for Patients with Pelvic Floor Dyssynergia-Type Constipation. <i>Diseases of the Colon and Rectum</i> , 2007, 50, 428-441.	0.7	266
98	Social learning contributions to the etiology and treatment of functional abdominal pain and inflammatory bowel disease in children and adults. <i>World Journal of Gastroenterology</i> , 2007, 13, 2397.	1.4	44
99	Biofeedback Is Superior to Laxatives for Normal Transit Constipation Due to Pelvic Floor Dyssynergia. <i>Gastroenterology</i> , 2006, 130, 657-664.	0.6	398
100	Design of Treatment Trials for Functional Gastrointestinal Disorders. <i>Gastroenterology</i> , 2006, 130, 1538-1551.	0.6	269
101	Hypnosis for Irritable Bowel Syndrome: The Empirical Evidence of Therapeutic Effects. <i>International Journal of Clinical and Experimental Hypnosis</i> , 2006, 54, 7-20.	1.1	43
102	Utility of red flag symptom exclusions in the diagnosis of irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 24, 137-146.	1.9	101
103	Hypnosis for non-cardiac chest pain. <i>Gut</i> , 2006, 55, 1381-1384.	6.1	15
104	Hypnosis Home Treatment for Irritable Bowel Syndrome: A Pilot Study. <i>International Journal of Clinical and Experimental Hypnosis</i> , 2006, 54, 85-99.	1.1	53
105	Reports of "Satisfactory Relief" by IBS Patients Receiving Usual Medical Care Are Confounded by Baseline Symptom Severity and Do Not Accurately Reflect Symptom Improvement. <i>American Journal of Gastroenterology</i> , 2006, 101, 1057-1065.	0.2	70
106	Biofeedback Benefits Only Patients With Outlet Dysfunction, Not Patients With Isolated Slow Transit Constipation. <i>Gastroenterology</i> , 2005, 129, 86-97.	0.6	328
107	Diagnosing and Managing Fecal Incontinence: If You Don't Ask, They Won't Tell. <i>Gastroenterology</i> , 2005, 129, 6.	0.6	48
108	The usual medical care for irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2004, 20, 1305-1315.	1.9	74

#	ARTICLE	IF	CITATIONS
109	Biofeedback Treatment for Functional Anorectal Disorders: A Comprehensive Efficacy Review. <i>Applied Psychophysiology Biofeedback</i> , 2004, 29, 153-174.	1.0	86
110	Elevated Vasoactive Intestinal Peptide Concentrations in Patients with Irritable Bowel Syndrome. <i>Digestive Diseases and Sciences</i> , 2004, 49, 1236-1243.	1.1	35
111	Control groups appropriate for behavioral interventions. <i>Gastroenterology</i> , 2004, 126, S159-S163.	0.6	43
112	Priorities for treatment research from different professional perspectives. <i>Gastroenterology</i> , 2004, 126, S180-S185.	0.6	19
113	Biofeedback Treatment of Constipation. <i>Diseases of the Colon and Rectum</i> , 2003, 46, 1208-1217.	0.7	130
114	Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders 1 1This study was registered with ClinicalTrials.gov (trial registry no.) Tj ETQq0 0 0 rgBT (Overlock) Tf 50 53	0.6	103
115	Factor analysis of bowel symptoms in US and Italian populations. <i>Digestive and Liver Disease</i> , 2003, 35, 774-783.	0.4	29
116	Sensory retraining is key to biofeedback therapy for formed stool fecal incontinence. <i>American Journal of Gastroenterology</i> , 2002, 97, 109-117.	0.2	124
117	Systematic review of the comorbidity of irritable bowel syndrome with other disorders: What are the causes and implications?. <i>Gastroenterology</i> , 2002, 122, 1140-1156.	0.6	944
118	AGA technical review on irritable bowel syndrome. <i>Gastroenterology</i> , 2002, 123, 2108-2131.	0.6	1,247
119	Anorectal functional testing: review of collective experience1. <i>American Journal of Gastroenterology</i> , 2002, 97, 232-240.	0.2	197
120	Hypnosis treatment for severe irritable bowel syndrome: investigation of mechanism and effects on symptoms. <i>Digestive Diseases and Sciences</i> , 2002, 47, 2605-2614.	1.1	172
121	Biofeedback for fecal incontinence and constipation: The role of medical management and education. <i>Gastroenterology</i> , 2001, 120, A397.	0.6	5
122	Biofeedback treatment of fecal incontinence. <i>Diseases of the Colon and Rectum</i> , 2001, 44, 728-736.	0.7	147
123	Treatment options for fecal incontinence. <i>Diseases of the Colon and Rectum</i> , 2001, 44, 131-142.	0.7	207
124	Further validation of the IBS-QOL: a disease-specific quality-of-life questionnaire. <i>American Journal of Gastroenterology</i> , 2000, 95, 999-1007.	0.2	340
125	Definition of a responder in clinical trials for functional gastrointestinal disorders: report on a symposium. <i>Gut</i> , 1999, 45, ii78-ii79.	6.1	23
126	Functional disorders of the anus and rectum. <i>Gut</i> , 1999, 45, ii55-ii59.	6.1	158

#	ARTICLE	IF	CITATIONS
127	AGA technical review on anorectal testing techniques. <i>Gastroenterology</i> , 1999, 116, 735-760.	0.6	419
128	Patient subgroups in irritable bowel syndrome that can be defined by symptom evaluation and physical examination. <i>American Journal of Medicine</i> , 1999, 107, 33-40.	0.6	23
129	3 Is functional dyspepsia just a subset of the irritable bowel syndrome?. <i>Bailliere's Clinical Gastroenterology</i> , 1998, 12, 443-461.	0.9	35
130	Is rectal pain sensitivity a biological marker for irritable bowel syndrome: Psychological influences on pain perception. <i>Gastroenterology</i> , 1998, 115, 1263-1271.	0.6	288
131	Irritable bowel syndrome: A technical review for practice guideline development. <i>Gastroenterology</i> , 1997, 112, 2120-2137.	0.6	521
132	Pain from rectal distension in women with irritable bowel syndrome: relationship to sexual abuse. <i>Digestive Diseases and Sciences</i> , 1997, 42, 796-804.	1.1	96
133	Standardization of barostat procedures for testing smooth muscle tone and sensory thresholds in the gastrointestinal tract. The Working Team of Glaxo-Wellcome Research, UK. <i>Digestive Diseases and Sciences</i> , 1997, 42, 223-241.	1.1	347
134	Mechanisms of Constipation in Older Persons and Effects of Fiber Compared with Placebo. <i>Journal of the American Geriatrics Society</i> , 1995, 43, 666-669.	1.3	91
135	Irritable bowel syndrome defined by factor analysis gender and race comparisons. <i>Digestive Diseases and Sciences</i> , 1995, 40, 2647-2655.	1.1	143
136	U. S. Householder survey of functional gastrointestinal disorders. <i>Digestive Diseases and Sciences</i> , 1993, 38, 1569-1580.	1.1	1,995
137	Existence of irritable bowel syndrome supported by factor analysis of symptoms in two community samples. <i>Gastroenterology</i> , 1990, 98, 336-340.	0.6	132
138	Tolerance for Rectosigmoid Distention in Irritable Bowel Syndrome. <i>Gastroenterology</i> , 1990, 98, 1187-1192.	0.6	579
139	Symptoms of Psychologic Distress Associated With Irritable Bowel Syndrome. <i>Gastroenterology</i> , 1988, 95, 709-714.	0.6	469
140	Habit Training as Treatment of Encopresis Secondary to Chronic Constipation. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 1985, 4, 397-401.	0.9	54
141	Irritable bowel syndrome. <i>Digestive Diseases and Sciences</i> , 1980, 25, 404-413.	1.1	455